Based on the ruling, products that are legal federally as well as at the state level can be reimbursed, which is a huge step forward, given that older policies prevented all cannabis-based substances from being reimbursed by insurance. However, we must be careful to take note of the nuances here; the ruling doesn’t treat cannabis as a primary medical treatment just yet but rather they are considered “specialized, non-primarily health-related benefits” by the Centers for Medicare and Medicaid Services (CMS).
A new collaboration brings together iconic functional glass, carefully selected cannabis genetics and a mission…
This interview by Micah Johnson originally appeared in High Times Local, produced under license by…
Congress's watchdog confirmed the DEA has no complete written procedures for drug scheduling. Learn why…
This column originally appeared in Cultivated, a cannabis industry newsletter. Subscribe here. You know the…
The DEA has opened a new registration process for state-licensed medical cannabis manufacturers, distributors and…
This November gathering will bring psychedelic education into conversation with music, visual art, comedy, philosophy,…